You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

133 Results
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • triptorelin
Jun 2017
These resources help nurse managers, nurse educators and registered nurses implement and meet the competency standards for registered nurses...
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) in combination with Chemotherapy - Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
May 2024
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Jun 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of metastatic gastric cancer (mGC) or adenocarcinoma of the gastroesophageal junction (GEJ) in adult patients, according to clinical criteria
Nov 2022
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jul 2025
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Curative
Mar 2021
Regimen
Cancer Type:
Genitourinary, 
Penile
Intent: Neoadjuvant, Palliative
Mar 2021
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sep 2023
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sep 2023
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
Updated
Sep 2025

Pages